|
Historical profiles of Mayo Clinic: The 1950 Novel Prize in Physiology or Medicine
|
On December 10, 1950, two Mayo Clinic staff members were awarded the Nobel Prize in physiology or medicine. They were researcher Edward Calvin Kendall, PhD, DSc (1886-1972), and clinician Philip Showalter Hench, MD, ScD (1896-1965). In addition, for work that paralleled and complemented that of Dr Kendall and Dr Hench, Tadeus Reichstein, PhD (1897-1996), of Basel, Switzerland, shared the award.
In the presentation speech, Professor G. Liljestrand, of the Royal Caroline Institute, said...
Related newspaper, magazine, and journal articles from HighBeam Research
|
MANAGEMENT OF RHEUMATOID ARTHRITIS.(TRIAD)
The News & Record (Piedmont Triad, NC)
; Byline: Robert M. Gay< Special to the News & Record Rheumatoid arthritis (RA) is a relatively common disease in which the lining or membranes of joints become inflamed ...
|
|
Quality of Life in American Indian and White Women With and Without Rheumatoid Arthritis
The American Journal of Occupational Therapy
; OBJECTIVE. The purpose of this study was to examine quality of life (QOL) in American Indian and White women with and without rheumatoid arthritis. METHOD. This cross-sectional study included 64 women in four groups: American Indians with rheumatoid arthritis, healthy American Indians, Whites with
|
|
Rheumatoid arthritis medication may extend life while easing pain
The Milwaukee Journal Sentinel
; Rheumatoid arthritis medication may extend life while easing pain By EMMA ROSS Associated Press Monday, April 15, 2002 London -- Methotrexate, a key drug for rheumatoid arthritis, could help people with the crippling disease live longer, new research suggests. Methotrexate, originally a cancer
|
|
Most Sjorgen's patients negative for RA antibodies.(Musculoskeletal Disorders)(rheumatoid arthritis)
Family Practice News
; Most patients with primary Sjorgen's syndrome test negative for anti-cyclic citrullinated peptide antibody and antikeratin antibodies, in contrast to patients with rheumatoid arthritis, a new study shows. However, primary Sjorgen's syndrome should not be ruled out in patients testing positive for
|
|
Anti-TNF therapy in early rheumatoid arthritis.(tumor necrosis factor)(Clinical report)
Bandolier
; Anti-TNF therapy for rheumatoid arthritis has a proven high degree of effectiveness (Bandolier 99) in clinical trials and the real world (Bandolier 104). In the main all these patients were already using disease-modifying drugs, or had failed to improve on them. Two new studies [1,2] suggest that
|